Individual patients may have substantial differences in their eGFRcr and eGFRcys for estimating kidney function, which has prognostic implications.

Povetacicept is an investigational dual BAFF and APRIL inhibitor being tested for various glomerulonephritis types in clinical trials.

Compared with eGFRcr, a 30% lower eGFRcys was associated with higher rates of all-cause mortality, cardiovascular events, and kidney disease.

National implementation of a race-neutral eGFR equation contributed to more modifications and higher kidney transplantation rates for Black candidates, according to study data published in the Journal ...

SAN DIEGO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced topline two-year confirmatory secondary endpoint results from the Company’s pivotal head-to-head ...